Navigation Links
Eurand to Present Zentase Phase III Data

MILAN, Italy, and DAYTON, Ohio, June 08, 2007 /PRNewswire-FirstCall/ --Eurand to present data on Zentase at European Cystic Fibrosis Society Annual Meeting. .

-- Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive

enzymes normally produced by the pancreas that can result from a number

of diseases, including cystic fibrosis, chronic pancreatitis, and

pancreatic cancer


-- EPI results in poor digestion and reduced absorption of nutrients

which, if untreated, can lead to impaired growth in children, impaired

immune response and shortened life expectancy


-- Treatment with pancreatic replacement products replaces enzymes lost

through this disease. Other than enzyme replacement, no known

alternative therapy for the loss of digestive enzymes is currently

available


-- Eurand completed two phase III clinical trials on its lead product

candidate, Zentase(TM), for the treatment of EPI


-- Eurand expects to initiate a rolling submission of its new drug

application (NDA) with the US Food and Drug Administration (FDA) for

Zentase for the treatment of EPI in the 2nd quarter of this year


-- Posters 243-246 will be presented on June 15th between 1:30-2:30pm:


1. Zentase, a New Pancreatic Enzyme Product (PEP), Is Safe and

Effective in Cystic Fibrosis (CF) Patients with Exocrine Pancreatic

Insufficiency (EPI)

2. Zentase, a New Pancreatic Enzyme Product (PEP), in Young Cystic

Fibrosis (CF) Patients with Exocrine Pancreatic Insufficiency (EPI)
< br /> 3. Child friendly dosing options for PEPs

4. Overfilling in Current Pancreatic Enzyme Products (PEPs): Still an

Unresolved Issue


For more information on Zentase and Eurand

Contact: Marian Cutler, Eurand, +1-973-517-0519

This media alert, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to Eurand's plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "expect" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as apart of our NDA filing. Forward looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

CONTACT: Marian Cutler of Eurand, +1-973-517-0519

Web site: http://www.eurand.com/

Ticker Symbol: (:EURX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand Announces Positive Phase III Clinical Study Results
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: ... five subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, ... specialty infusion services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat ... "As we continue to build ...
(Date:12/7/2016)... SCIENCE PARK , Israel , ... (TASE: KDST) announced today the signing of a memorandum of understanding ... companies. The synergy between the companies will assist in expediting Kadimastem,s ... worldwide leader in innovative treatment for severe diseases in general and ... , ...
(Date:12/7/2016)...  Based on its recent analysis of ... Sullivan recognizes Nemaura Pharma Limited with the ... Enabling Technology Leadership. Nemaura Pharma,s transdermal drug ... drug delivery technologies, especially in delivering biologics. ... technologies, Memspatch and Micropatch respectively, facilitate minimally ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to ... Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip ... zones. Editors can select from a variety of flip book animations. In Addition, users ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... The ... Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This premier event ... range of experiences from a cross-section of industries such as financial services, insurance, ...
(Date:12/7/2016)... Warwick, New York (PRWEB) , ... December 07, 2016 , ... ... computer professor at Yale had described him as 'a genius.'" Thus begins "Margaret in ... R. L. Rhyse and published by Wyston Books, Inc. These novels narrate ...
Breaking Medicine News(10 mins):